Sickle Cell Disease Trial, Recruiting NCT02824471 Sponsor: University Hospitals Cleveland Medical Center Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Sickle Cell Disease Trial, Recruiting

NCT02824471
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 12 years of age or older at the time of signing up for the trial
  • People who have a confirmed diagnosis of Sickle Cell Disease, specifically the HbSS type, or related forms called HbSC or HbSβ-thalassemia, shown by one or more clinical signs or features
  • People (or their legal representatives) who are able to provide written consent to participate, and who are able to follow the requirements of the study

Who may not be able to join:

  • People who have any condition or health abnormality that, in the trial doctor's judgment, could put the patient's safety at risk or affect the reliability of the study results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Amma Owusu-Ansah, MD, University Hospitals Cleveland Medical Center

Phone: (216) 368-6447

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospitals Cleveland Medical Center
Registry
ClinicalTrials.gov
Start date
1 October 2014
Est. completion
31 May 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Develop an SCD Biochip with which to examine key cellular properties and interactions, including RBC and WBC cellular, adhesive, and inflammatory properties, and circulating endothelial and hematopoietic precursor cell characteristics.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov